| Virksomhedsstatus | | NORMAL. |
| Sidst opdateret den 22.02.2019 og
angivet som gældende fra 13.02.2019 (2091
dage). |
Ingen historik.
| Branche | | Fremstilling af farmaceutiske præparater (212000). |
| Sidst opdateret den 22.02.2019 og
angivet som gældende fra 13.02.2019 (2091
dage). |
Ingen historik.
| Revisionfravalgt | | false. |
| Sidst opdateret den 11.11.2020 og
angivet som gældende fra 29.10.2020 (1467
dage). |
| Historik | Start | Stop |
|---|
| false | 29.10.2020 | |
| true | 13.02.2019 | 28.10.2020 |
Ingen nuværende registrering.
Ingen historik.
Ingen nuværende registrering.
Ingen historik.
| Navne | | Breye Therapeutics ApS. |
| Sidst opdateret den 18.11.2022 og
angivet som gældende fra 04.11.2022 (731
dage). |
| Historik | Start | Stop |
|---|
| Breye Therapeutics ApS | 04.11.2022 | |
| Ciana Therapeutics ApS | 25.08.2020 | 03.11.2022 |
| Visus Therapeutics ApS | 13.02.2019 | 24.08.2020 |
| Binavne | | Ciana Therapeutics ApS. |
| Sidst opdateret den 22.11.2022 og
angivet som gældende fra 22.11.2022 (713
dage). |
| Historik | Start | Stop |
|---|
| Ciana Therapeutics ApS | 22.11.2022 | |
| Visus Therapeutics ApS | 26.08.2020 | 14.11.2022 |
| Tegningsregel | | Selskabet tegnes af bestyrelsesformanden i forening med et bestyrelsesmedlem eller af bestyrelsesformanden i forening med en direktør eller af den samlede bestyrelse. |
| Sidst opdateret den 18.11.2022 og
angivet som gældende fra 18.11.2022 (717
dage). |
| Fortolkning
(3 tegningsmuligheder)
| | formanden + 1 bestyrelsesmedlem |
| formanden + 1 direktør |
| bestyrelsen |
| Historik | Start | Stop |
|---|
| Selskabet tegnes af bestyrelsesformanden i forening med et bestyrelsesmedlem eller af bestyrelsesformanden i forening med en direktør eller af den samlede bestyrelse | 18.11.2022 | |
| Selskabet tegnes af direktionen | 13.02.2019 | 17.11.2022 |
Type af revisorbistand:Revisionspåtegning
Navn på revisionsvirksomhed:EY Godkendt Revisionspartnerselskab
Revisionsvirksomhedens CVR-nr.:30700228
Beskrivelse af revisor:State Authorised Public Accountant
Virksomhedens regnskabsklasse:Regnskabsklasse B
Grundlag for konklusion (revision):We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the "Auditor's responsibilities for the audit of the financial statements" section of our report. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.
Independence
We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' International Code of Ethics for Professional Accountants (IESBA Code) and the additional ethical requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the IESBA Code.
Konklusion (revision):We have audited the financial statements of Breye Therapeutics ApS for the financial year 1 April 2023 - 31 March 2024, which comprise income statement, balance sheet, statement of changes in equity and notes, including accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.
In our opinion, the financial statements give a true and fair view of the financial position of the Company at 31 March 2024 and of the results of the Company's operations for the financial year 1 April 2023 - 31 March 2024 in accordance with the Danish Financial Statements Act.
Udtalelse om ledelsesberetningen (revision):Management is responsible for the Management's review.
Our opinion on the financial statements døs not cover the Management's review, and we do not express any form of assurance conclusion thereon.
In connection with our audit of the financial statements, our responsibility is to read the Management's review and, in doing so, consider whether the Management's review is materially inconsistent with the financial statements or our knowledge obtained during the audit, or otherwise appears to be materially misstated.
Moreover, it is our responsibility to consider whether the Management's review provides the information required under the Danish Financial Statements Act.
Based on the work we have performed, we conclude that the Management's review is in accordance with the financial statements and has been prepared in accordance with the requirements of the Danish Financial Statement Act. We did not identify any material misstatement of the Management's review.
Ingen nuværende registrering.
Ingen historik.
Ingen nuværende registrering.
Ingen historik.
Ingen nuværende registrering.
Ingen historik.
LoginOpret gratis brugere-conomic integration